RxSight (RXST) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

RXST Stock Forecast

RxSight stock forecast is as follows: an average price target of $70.14 (represents a 108.38% upside from RXST’s last price of $33.66) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.

RXST Price Target

The average price target for RxSight (RXST) is $70.14 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $110.00 to $52.00. This represents a potential 108.38% upside from RXST's last price of $33.66.

RXST Analyst Ratings

Buy

According to 8 Wall Street analysts, RxSight's rating consensus is 'Buy'. The analyst rating breakdown for RXST stock is 0 'Strong Buy' (0.00%), 8 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

RxSight Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Oct 29, 2024	Anthony Crowdell	Mizuho Securities	$67.00	$52.00	28.85%	99.05%
Oct 29, 2024	Adam Seiden	Barclays	$110.00	$52.00	111.54%	226.80%
Oct 29, 2024	Curry Baker	Guggenheim	$52.00	$52.00	-	54.49%
Oct 29, 2024	Young Li	Jefferies	$72.00	$50.25	43.28%	113.90%
Sep 23, 2024	Ryan Zimmerman	BTIG	$59.00	$52.98	11.36%	75.28%
Sep 13, 2024	David Saxon	Needham	$66.00	$54.54	21.01%	96.08%
Aug 06, 2024	Thomas Stephan	Stifel Nicolaus	$65.00	$40.78	59.39%	93.11%
Aug 06, 2024	David Saxon	Needham	$54.00	$47.15	14.54%	60.43%
May 07, 2024	Steven Lichtman	Oppenheimer	$72.00	$62.84	14.58%	113.90%
May 07, 2024	David Saxon	Needham	$75.00	$62.84	19.35%	122.82%
May 07, 2024	Tom Stephan	Stifel Nicolaus	$75.00	$62.84	19.35%	122.82%
May 07, 2024	Lawrence Biegelsen	Wells Fargo	$68.00	$62.84	8.21%	102.02%
May 07, 2024	Ryan Zimmerman	BTIG	$72.00	$62.84	14.58%	113.90%
May 06, 2024	Thomas Stephan	Stifel Nicolaus	$68.00	$61.68	10.25%	102.02%
Dec 13, 2023	Lawrence Biegelsen	Wells Fargo	$42.00	$39.78	5.58%	24.78%
Jul 12, 2023	David Saxon	Needham	$34.00	$30.86	10.17%	1.01%

The latest RxSight stock forecast, released on Oct 29, 2024 by Anthony Crowdell from Mizuho Securities, set a price target of $67.00, which represents a 28.85% increase from the stock price at the time of the forecast ($52.00), and a 99.05% increase from RXST last price ($33.66).

RxSight Price Target by Period

	1M	3M	12M
# Anlaysts	-	5	14
Avg Price Target	-	$72.00	$69.64
Last Closing Price	$33.66	$33.66	$33.66
Upside/Downside	-100.00%	113.90%	106.89%

In the current month, the average price target of RxSight stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to RxSight's last price of $33.66. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 29, 2024	Barclays		Overweight	Initialise
Oct 29, 2024	Rodman & Renshaw		Buy	Initialise
Oct 29, 2024	Guggenheim		Buy	Initialise
Oct 29, 2024	Wells Fargo	Buy	Buy	Hold
Oct 29, 2024	Jefferies		Buy	Initialise
Sep 23, 2024	BTIG	Buy	Buy	Hold
Sep 13, 2024	Wells Fargo	Buy	Buy	Hold
Sep 13, 2024	Stifel Nicolaus	Underperform	Underperform	Hold
Sep 13, 2024	Needham	Buy	Buy	Hold
Aug 06, 2024	Needham	Buy	Buy	Hold
Aug 06, 2024	Oppenheimer	Outperform	Outperform	Hold
May 07, 2024	Stifel Nicolaus	Buy	Buy	Hold
May 07, 2024	Oppenheimer	Outperform	Outperform	Hold
May 07, 2024	Needham	Buy	Buy	Hold
May 07, 2024	Wells Fargo	Overweight	Overweight	Hold
May 06, 2024	BTIG	Buy	Buy	Hold
Dec 13, 2023	Wells Fargo		Overweight	Upgrade
Jul 12, 2023	Needham	Buy	Buy	Hold

RxSight's last stock rating was published by Barclays on Oct 29, 2024. The company Initialise its RXST rating from "null" to "Overweight".

RxSight Financial Forecast

RxSight Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	$30.67M	$29.61M	$17.49M	$16.09M	$12.62M	$11.36M	$8.94M	$8.43M	$5.79M	$4.90M
Avg Forecast	$71.61M	$60.81M	$59.84M	$50.32M	$53.96M	$46.90M	$46.68M	$40.58M	$40.39M	$35.06M	$32.33M	$27.56M	$28.25M	$20.55M	$19.23M	$16.28M	$15.85M	$10.98M	$10.55M	$7.32M	$7.64M	$5.22M	$4.92M
High Forecast	$74.20M	$63.00M	$62.00M	$52.13M	$55.91M	$48.59M	$48.36M	$41.68M	$40.61M	$35.26M	$32.33M	$27.56M	$29.27M	$20.55M	$19.92M	$16.87M	$16.42M	$10.98M	$10.55M	$7.32M	$7.64M	$5.22M	$4.92M
Low Forecast	$69.83M	$59.29M	$58.35M	$49.06M	$52.62M	$45.73M	$45.51M	$38.99M	$39.96M	$34.87M	$32.33M	$27.56M	$27.54M	$20.55M	$18.75M	$15.88M	$15.45M	$10.98M	$10.55M	$7.32M	$7.64M	$5.22M	$4.92M
# Analysts	2	2	2	2	1	1	1	4	7	3	2	2	4	2	2	2	1	1	1	1	2	2	2
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.49%	1.54%	1.07%	1.02%	1.15%	1.08%	1.22%	1.10%	1.11%	1.00%

RxSight's average Quarter revenue forecast for Dec 23 based on 4 analysts is $28.25M, with a low forecast of $27.54M, and a high forecast of $29.27M. RXST's average Quarter revenue forecast represents a -7.89% decrease compared to the company's last Quarter revenue of $30.67M (Sep 23).

RxSight EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21
# Analysts	2	2	2	2	1	1	1	4	7	3	2	2	4	2	2	2	1	1	1	1	2	2	2
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	$-12.51M	$-13.63M	$-11.71M	$-14.15M	$-14.54M	$-14.55M	$-15.50M	$-13.63M	$-10.59M	$-12.87M
Avg Forecast	$-6.60M	$-5.60M	$-5.51M	$-4.64M	$-4.97M	$-4.32M	$-4.30M	$-3.74M	$-3.72M	$-3.23M	$-2.98M	$-2.54M	$-2.60M	$-1.89M	$-1.77M	$-1.50M	$-1.46M	$-9.91M	$-9.53M	$-15.74M	$-6.90M	$-10.00M	$-4.44M
High Forecast	$-6.43M	$-5.46M	$-5.38M	$-4.52M	$-4.85M	$-4.21M	$-4.19M	$-3.59M	$-3.68M	$-3.21M	$-2.98M	$-2.54M	$-2.54M	$-1.89M	$-1.73M	$-1.46M	$-1.42M	$-9.91M	$-9.53M	$-12.59M	$-6.90M	$-8.00M	$-4.44M
Low Forecast	$-6.84M	$-5.81M	$-5.71M	$-4.80M	$-5.15M	$-4.48M	$-4.46M	$-3.84M	$-3.74M	$-3.25M	$-2.98M	$-2.54M	$-2.70M	$-1.89M	$-1.84M	$-1.55M	$-1.51M	$-9.91M	$-9.53M	$-18.88M	$-6.90M	$-12.00M	$-4.44M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	6.61%	7.69%	7.80%	9.69%	1.47%	1.53%	0.98%	1.98%	1.06%	2.90%

undefined analysts predict RXST's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than RxSight's previous annual EBITDA (undefined) of $NaN.

RxSight Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21
# Analysts	2	2	2	2	1	1	1	4	7	3	2	2	4	2	2	2	1	1	1	1	2	2	2
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	$-12.41M	$-13.80M	$-14.83M	$-15.61M	$-17.68M	$-17.67M	$-17.60M	$-15.73M	$-12.67M	$-13.48M
Avg Forecast	$9.75M	$9.92M	$9.73M	$6.81M	$-232.41K	$-3.49M	$-2.69M	$-5.25M	$-6.58M	$-9.80M	$-8.87M	$-11.71M	$-14.66M	$-17.24M	$-18.72M	$-21.09M	$-29.81M	$-27.46M	$-25.67M	$-17.87M	$-23.49M	$-11.97M	$-25.69M
High Forecast	$10.21M	$10.38M	$10.19M	$7.13M	$-224.88K	$-3.38M	$-2.60M	$-5.08M	$-2.63M	$-9.48M	$-8.58M	$-11.33M	$-13.03M	$-16.68M	$-18.11M	$-20.41M	$-28.85M	$-27.46M	$-25.67M	$-14.29M	$-23.49M	$-9.58M	$-25.69M
Low Forecast	$9.44M	$9.60M	$9.42M	$6.59M	$-243.32K	$-3.65M	$-2.82M	$-5.50M	$-9.21M	$-10.26M	$-9.28M	$-12.26M	$-16.29M	$-18.05M	$-19.60M	$-22.08M	$-31.21M	$-27.46M	$-25.67M	$-21.44M	$-23.49M	$-14.36M	$-25.69M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.72%	0.74%	0.70%	0.52%	0.64%	0.69%	0.98%	0.67%	1.06%	0.52%

RxSight's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. RXST's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

RxSight SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21
# Analysts	2	2	2	2	1	1	1	4	7	3	2	2	4	2	2	2	1	1	1	1	2	2	2
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	$19.14M	$18.24M	$16.25M	$15.73M	$14.93M	$14.39M	$13.62M	$11.62M	$9.08M	$6.50M
Avg Forecast	$161.94M	$137.51M	$135.31M	$113.78M	$122.03M	$106.06M	$105.55M	$91.76M	$91.34M	$79.29M	$73.10M	$62.32M	$63.88M	$46.48M	$43.48M	$36.82M	$35.84M	$24.83M	$23.86M	$16.55M	$17.28M	$11.81M	$11.12M
High Forecast	$167.79M	$142.47M	$140.20M	$117.89M	$126.44M	$109.89M	$109.36M	$94.24M	$91.84M	$79.73M	$73.10M	$62.32M	$66.18M	$46.48M	$45.05M	$38.15M	$37.13M	$24.83M	$23.86M	$16.55M	$17.28M	$11.81M	$11.12M
Low Forecast	$157.90M	$134.08M	$131.94M	$110.95M	$118.99M	$103.42M	$102.92M	$88.17M	$90.36M	$78.86M	$73.10M	$62.32M	$62.29M	$46.48M	$42.40M	$35.90M	$34.95M	$24.83M	$23.86M	$16.55M	$17.28M	$11.81M	$11.12M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.41%	0.42%	0.44%	0.44%	0.60%	0.60%	0.82%	0.67%	0.77%	0.58%

RxSight's average Quarter SG&A projection for Dec 23 is $63.88M, based on 4 Wall Street analysts, with a range of $62.29M to $66.18M. The forecast indicates a 233.70% rise compared to RXST last annual SG&A of $19.14M (Sep 23).

RxSight EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21
# Analysts	2	2	2	2	1	1	1	4	7	3	2	2	4	2	2	2	1	1	1	1	2	2	2
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.00	$-0.00	$-0.47	$-0.56	$-0.64	$-0.64	$-0.64	$-0.58	$-0.68	$-0.51
Avg Forecast	$0.25	$0.25	$0.24	$0.17	$-0.01	$-0.09	$-0.07	$-0.13	$-0.17	$-0.25	$-0.22	$-0.29	$-0.37	$-0.43	$-0.47	$-0.53	$-0.75	$-0.71	$-0.67	$-0.59	$-0.61	$-0.61	$-0.67
High Forecast	$0.26	$0.26	$0.26	$0.18	$-0.01	$-0.08	$-0.07	$-0.13	$-0.07	$-0.24	$-0.22	$-0.28	$-0.33	$-0.42	$-0.46	$-0.51	$-0.73	$-0.71	$-0.67	$-0.59	$-0.61	$-0.61	$-0.67
Low Forecast	$0.24	$0.24	$0.24	$0.17	$-0.01	$-0.09	$-0.07	$-0.14	$-0.23	$-0.26	$-0.23	$-0.31	$-0.41	$-0.45	$-0.49	$-0.55	$-0.78	$-0.71	$-0.67	$-0.59	$-0.61	$-0.61	$-0.67
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00%	0.00%	0.89%	0.75%	0.90%	0.96%	1.08%	0.95%	1.12%	0.76%

According to undefined Wall Street analysts, RxSight's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to RXST previous annual EPS of $NaN (undefined).

RxSight Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
APYX	Apyx Medical	$1.64	$8.50	418.29%	Buy
LUNG	Pulmonx	$6.13	$13.00	112.07%	Buy
SGHT	Sight Sciences	$3.62	$7.50	107.18%	Hold
RXST	RxSight	$38.04	$70.14	84.38%	Buy
KIDS	OrthoPediatrics	$22.46	$39.50	75.87%	Buy
OFIX	Orthofix Medical	$17.93	$24.00	33.85%
SIBN	SI-BONE	$13.84	$18.50	33.67%	Buy
NPCE	NeuroPace	$11.52	$15.00	30.21%	Buy
IRMD	IRadimed	$53.00	$60.00	13.21%	Buy
VREX	Varex Imaging	$15.16	$17.00	12.14%	Buy
FNA	Paragon 28	$10.36	$11.50	11.00%	Buy
CVRX	CVRx	$13.16	$14.25	8.28%	Buy

RXST Forecast FAQ

Is RxSight a good buy?

Yes, according to 8 Wall Street analysts, RxSight (RXST) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 8 'Buy' recommendations, accounting for 100.00% of RXST's total ratings.

What is RXST's price target?

RxSight (RXST) average price target is $70.14 with a range of $52 to $110, implying a 108.38% from its last price of $33.66. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will RxSight stock go up soon?

According to Wall Street analysts' prediction for RXST stock, the company can go up by 108.38% (from the last price of $33.66 to the average price target of $70.14), up by 226.80% based on the highest stock price target, and up by 54.49% based on the lowest stock price target.

Can RxSight stock reach $50?

RXST's average twelve months analyst stock price target of $70.14 supports the claim that RxSight can reach $50 in the near future.

What are RxSight's analysts' financial forecasts?

RxSight's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $188.12M (high $194.54M, low $182.85M), average EBITDA is $-17.333M (high $-16.848M, low $-17.925M), average net income is $-11.665M (high $-11.288M, low $-12.213M), average SG&A $425.4M (high $439.93M, low $413.5M), and average EPS is $-0.293 (high $-0.284, low $-0.307). RXST's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $242.57M (high $251.33M, low $236.53M), average EBITDA is $-22.35M (high $-21.793M, low $-23.158M), average net income is $36.22M (high $37.92M, low $35.04M), average SG&A $548.54M (high $568.36M, low $534.88M), and average EPS is $0.91 (high $0.953, low $0.881).

Did the RXST's actual financial results beat the analysts' financial forecasts?

Based on RxSight's last annual report (Dec 2022), the company's revenue was $49M, beating the average analysts forecast of $44.7M by 9.64%. Apple's EBITDA was $-61.801M, beating the average prediction of $-36.634M by 68.70%. The company's net income was $-66.756M, missing the average estimation of $-101M by -33.78%. Apple's SG&A was $58.66M, missing the average forecast of $101.07M by -41.96%. Lastly, the company's EPS was $-2.41, missing the average prediction of $-2.723 by -11.48%. In terms of the last quarterly report (Sep 2023), RxSight's revenue was $30.67M, beating the average analysts' forecast of $20.55M by 49.21%. The company's EBITDA was $-12.512M, beating the average prediction of $-1.894M by 560.72%. RxSight's net income was $-12.415M, missing the average estimation of $-17.242M by -27.99%. The company's SG&A was $19.14M, missing the average forecast of $46.48M by -58.81%. Lastly, the company's EPS was $-0.0003, missing the average prediction of $-0.433 by -99.93%